CD226 and AL amyloidosis: Soriani et al. (49) noted that myeloma cells treated with low doses of therapeutic agents (e.g., doxorubicin, melphalan, bortezomib) used commonly in patients with multiple myeloma up-regulated expression of DNAM-1 and NKG2D ligands.